TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05400785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Rhythms for Mood (CRM) application - Active
Description: The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Circadian Rhythms for Mood (CRM) application - Sham
Description: The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
Study: NCT05320679

Intervention type: OTHER
Intervention: Implementation of Questionnaire
Description: Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
Study: NCT06062914

Intervention type: DRUG
Intervention: oral nutritional supplements
Description: Only ONS was used as enteral nutrition
Study: NCT06157710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention through modules
Description: * Introduction~* Goal Setting Techniques~* Motivation~* Barriers to Action~* Managing Maladaptive Thoughts and Beliefs~* Value Clarification~* Moving Forward
Study: NCT05820958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shantali massage
Description: The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~* face and chest; 4 types of movements 10reps each;~* upper extremity; 4 types of movements, 10 reps each (left and right separately);~* abdomen; 2 types of movements, 10 reps each;~* lower extremity; 3 types of movements, 10 reps each (left and right separately);~* back; 2 types of movements, 10 reps each;~* final integration; 3 types of movements, 10 reps each.
Study: NCT06267963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral [14C]PF-07220060
Description: A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-07220060
Description: A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV [14C] PF-07220060
Description: A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
Study: NCT05398614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SENL101
Description: Patients will be treated with CD7 CAR-T cells
Study: NCT06294080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Exercise intervention
Study: NCT05823740

Intervention type: OTHER
Group type: OTHER
Intervention: Bioelectrical impedance Analysis (BIA)
Description: Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: D3-Creatine Dilution (D3Cr)
Description: The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: 6-Minute Walk Test (6MWT)
Description: Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Timed Up and Go (TUG)
Description: Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: 30-second Sit-to-Stand (STS)
Description: Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand Grip Strength (GS)
Description: Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: PBTL p16 expression
Description: Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: CT, MR and PET Imaging
Description: Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
Study: NCT05179993

Intervention type: OTHER
Intervention: Microplastics
Description: Detection of microplastics as a yes/no value
Study: NCT06203522

Intervention type: PROCEDURE
Intervention: Data collection of successful completion of MRI
Description: age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
Study: NCT05261854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback
Description: Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercises for deep cervical muscle training
Description: Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
Study: NCT04384237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser-aided CSF
Description: After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CSF
Description: After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
Study: NCT05647330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Combined With Gemcitabine
Description: Hydroxychloroquine combined with chemotherapy
Study: NCT04566484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBV87 Chikungunya vaccine
Description: BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline is the placebo
Study: NCT04290845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relief-Hybrid
Description: A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
Study: NCT06091345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: • Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: • Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albumin
Description: • Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT05205759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bamlanivimab Etesevimab
Description: Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casirivimab-Imdevimab
Description: Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
Study: NCT05165680

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of aerobic exercise and healthy diet
Description: The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination of aerobic exercise and healthy diet
Description: The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks
Study: NCT04869787

Intervention type: DEVICE
Group type: OTHER
Intervention: Selective Cytopheretic Device
Description: SCD in line with CRRT extracorporeal device
Study: NCT04951323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
Description: Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
Study: NCT05251402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Patient Education
Description: If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Patient Education with Nutrition Counseling
Description: If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term.
Study: NCT05457621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effaclar serum
Description: Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
Study: NCT06526780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchscopy
Description: Bronchscopy in critical ill children with airway diseases
Study: NCT05316714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafing
Description: NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
Study: NCT06037356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift
Description: Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
Study: NCT04320524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
Description: 3 weeks
Study: NCT06481137

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiological study (EP study)
Description: Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ePatch (extended Holter Monitoring)
Description: Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ePatch (extended Holter Monitoring)
Description: Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
Study: NCT05022667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTeye
Description: The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
Study: NCT05593848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratissue Percutaneous Electrolysis
Description: Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
Study: NCT05953636

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)
Description: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)
Description: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)
Description: oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
Study: NCT04661397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
Study: NCT05760872

Intervention type: OTHER
Intervention: Placing esophageal probe
Description: Placing an esophageal probe through the mouth
Study: NCT04719949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) Therapy
Description: Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy (PST)
Description: Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
Study: NCT05778448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality
Description: A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality
Description: A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality
Description: A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).